A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation-specific monoclonal antibody

Journal of Virological Methods

Volumn 80, Issue 1, 1999, Pages 85-96

  Jiang, Shibo ^a   Lin, Kang ^a   Zhang, Li ^a   Debnath, Asim K ^a  

^a NEW YORK BLOOD CENTER   (United States)

Author keywords

Antiviral agents; Cell fusion; gp41; Monoclonal antibody; Screening assay

Indexed keywords

ANTIVIRUS AGENT; GLYCOPROTEIN GP 41; PEPTIDE;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG SCREENING; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN IMMUNODEFICIENCY VIRUS 1; MUTATION; NONHUMAN; PRIORITY JOURNAL; TECHNIQUE;

AMINO ACID SEQUENCE; ANTI-HIV AGENTS; ANTIBODIES, MONOCLONAL; CELL FUSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDES; POINT MUTATION; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0033041322     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-0934(99)00041-5     Document Type: Article

References (36)

1. Balzarini J., Mitsuya H., De Clercq E., Broder S. Aurintricarboxylic acid and Evans Blue represent two different classes of anionic compounds which selectively inhibit the cytopathogenicity of human T-cell lymphotropic virus type III/lymphadenopathy-associated virus. Biochem. Biophys. Res. Commun. 136:1986;64-71.
2. Berger E.A. HIV entry and tropism: the chemokine receptor connection. AIDS (Suppl A). 11:1997;S3-16.
3. Bernstein H.B., Tucker S.P., Kar S.R. et al. Oligomerization of the hydrophobic heptad repeat of gp41. J. Virol. 69:1995;2745-2750.
4. Caffrey M., Cai M., Kaufman J. et al. Three-dimensional solution structure of the 44 kDa ectodomain of SIV gp41. EMBO J. 17:1998;4572-4584.
5. Cao J., Bergeron L., Helseth E., Thali M., Repke H., Sodroski J. Effects of amino acid changes in the extracellular domain of the human imunodeficiency virus type 1 gp41 envelope glycoprotein. J. Virol. 67:1993;2747-2755.
6. Chan D.C., Fass D., Berger J.M., Kim P.S. Core structure of gp41 from the HIV envelope glycoprotein. Cell. 89:1997;263-273.
7. Chan D.C., Kim P.S. HIV entry and its inhibition. Cell. 93:1998;681-684.
8. Chen C.H., Matthews T.J., McDanal C.B., Bolognesi D.P., Greenberg M.L. A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion. J. Virol. 69:1995;3771-3777.
9. Chen S.S., Lee C.N., Lee W.R., Mcintosh K., Lee T.H. Mutational analysis of the leucine zipper-like motif of the human immunodeficiency virus type 1 envelope transmembrane glycoprotein. J. Virol. 67:1993;3615-3619.
10. Debnath A.K., Jiang S., Neurath A.R. Molecular modeling of the V3 loop of the HIV-1 envelope glycoprotein gp120 reveals a possible binding pocket for porphyrins. Sanz F., Giraldo J., Manaut F. QSAR and Molecular Modeling: Concepts, Computational Tools and Biological Applications. 1995;585-587 J.R. Prous Science Publishers, Barcelona.
11. Delwart E.L., Mosialos G., Gilmore T. Retroviral envelope glycoproteins contain a leucine zipper-like repeat. AIDS Res. Hum. Retroviurses. 6:1990;703-706.
12. Furuta R., Wild C.T., Weng Y., Weiss C.D. Capture of an early fusion-active conformation of HIV-1 gp41. Nat. Struct. Biol. 5:1998;276-279.
13. Gallaher W.R., Ball J.M., Garry R.F., Griffin M.C., Montelaro R.C. A general model for the transmembrane proteins of HIV and other retroviruses. AIDS Res. Hum. Retroviruses. AIDS Res. Hum. Retroviruses. 5:1989;431-440.
14. Hunter E. gp41, a multifunctional protein involved in HIV entry and pathogensis. Korber B., Hahn B., Foley B., Mellors J.W., Leitner T., Myers G., McCutchan F., Kuiken C. Human Retroviruses and AIDS 1997. 1997;III55-III73 Los Alamos National Laboratory, Los Alamos, New Mexico.
15. Jiang S., Lin K., Neurath A.R. Enhancement of human immunodeficiency virus type-1 (HIV-1) infection by antisera to peptides from the envelope glycoproteins gp120/gp41. J. Exp. Med. 174:1991;1557-1563.
16. Jiang S., Lin K., Strick N., Neurath A.R. HIV-1 inhibition by a peptide. Nature. 365:1993;113.
17. Jiang S., Lin K. Effect of modification of a peptide derived from the HIV-1 gp41 sequences on the antiviral activity. Peptide Res. 8:1995;345-348.
18. Jiang S., Lin K., Lu M. A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the HIV-1 envelope glycoprotein. J. Virol. 72:1998;10213-10217.
19. Kilby J.M., Hopkins S., Venetta T.M. et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nature Med. 4:1998;1302-1307.
20. Lu M., Blacklow S.C., Kim P.S. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat. Struct. Biol. 2:1995;1075-1082.
21. Lu M., Kim P.S. A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein. J. Biochem. Struct. Dynamic. 15:1997;465-471.
22. Moore J.P., Jameson B.A., Weiss R.A., Sattentau Q.J. The HIV-cell fusion reaction. Bentz J. Viral Fusion Mechanisms. 1993;233-289 CRC Press, Boca Raton.
23. Murakami T., Nakajima T., Koyanagi Y. et al. A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. J. Exp. Med. 186:1997;1389-1393.
24. Neurath A.R., Haberfield P., Joshi B., Hewlett I.K., Strick N., Jiang S. Rapid prescreening for antiviral agents against HIV-1 based on their inhibitory activity in site-directed immunoassays I: The V3 loop of gp120 as target. Antiv. Chem. Chemother. 2:1991;303-312.
25. Neurath A.R., Strick N., Haberfield P., Jiang S. Rapid prescreening for antiviral agents against HIV-1 based on their inhibitory activity in site-directed immunoassays II: porphyrins reacting with the V3 loop of gp120. Antiv. Chem. Chemother. 31:1992;55-63.
26. Neurath A.R., Strick N., Jiang S. Synthetic peptides and anti-peptide antibodies as probes to study inter-domain interactions involved in virus assemble: the envelope of the human immunodeficiency virus (HIV-1). Virology. 188:1992;1-13.
27. Neurath A.R., Strick N., Lin K., Debnath A.K., Jiang S. Tin protoporphyrin IX used in control of heme metabolism in humans effectively inhibits HIV-1 infection. Antiv. Chem. Chemother. 5:1994;322-330.
28. Neurath A.R., Jiang S., Strick N., Lin K., Li Y.-Y., Debnath A.K. Bovine 8-lactoglobulin modified by 3-hydroxyphthalic anhydride blocks the CD4 cell receptors for HIV-1. Nature Med. 2:1996;230-234.
29. Poumbourios P., Wilson K.A., Center R.J., El Ahmar R., Kemp B.E. Human immunodeficiency virus type 1 envelope glycoprotein oligomerization requires the gp41 amphipathic alpha-helical/ leucine zipper-like sequence. J. Virol. 71:1997;2041-2049.
30. Schols D., Baba M., Pauwels R., Desmyter J., De Clercq E. Specific interaction of aurintricarboxylic acid with the human immunodeficiency virus/CD4 cell receptor. Proc. Natl. Acad. Sci. USA. 86:1989;3322-3326.
31. Tan K., Liu J., Wang J., Shen S., Liu M. Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc. Natl. Acad. Sci. 94:1997;12303-12308.
32. Weissenhorn W., Dessen A., Harrison S.C., Skehel J.J., Wiley D.C. Atomic structure of the ectodomain from HIV-1 gp41. Nature. 387:1997;426-428.
33. Wild C., Oas T., McDanal C., Bolognesi D., Matthews T. A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc. Natl. Acad. Sci. USA. 89:1992;10537-10541.
34. Wild C.T., Shugars D.C., Greenwell T.K., McDanal C.B., Matthews T.J. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl. Acad. Sci. USA. 91:1994;9770-9774.
35. Wild C., Dubay J.W., Greenwell T. et al. Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex. Proc. Natl. Acad. Sci. USA. 91:1994;12676-12680.
36. Wild C., Greenwell T., Shugars D., Rimsky-Clarke L., Matthews T. The inhibitory activity of an HIV type 1 peptide correlates with its ability to interact with a leucine zipper structure. AIDS Res. Hum. Retroviruses. 11:1995;323-325.